Nukast AB Tablet SR is a combination medication containing Acebrophylline 200mg and Montelukast 10mg, formulated to provide sustained relief in respiratory conditions characterized by bronchoconstriction and inflammation. Acebrophylline acts as a bronchodilator with mucolytic properties, facilitating airway clearance by reducing mucus viscosity and improving respiratory function. Montelukast, a leukotriene receptor antagonist, effectively inhibits leukotriene-mediated bronchoconstriction and inflammation, contributing to long-term control of asthma and allergic rhinitis symptoms. This synergistic combination is indicated for the management of chronic obstructive pulmonary disease (COPD), bronchial asthma, and other obstructive airway diseases where both bronchospasm and airway inflammation coexist. Nukast AB Tablet SR is designed for once-daily administration, ensuring sustained therapeutic plasma levels and improved patient compliance. It is generally well-tolerated; however, clinicians should monitor for potential adverse effects such as headache, gastrointestinal disturbances, or hypersensitivity reactions. It is contraindicated in patients with known hypersensitivity to either component. As with all bronchodilators and anti-inflammatory agents, careful assessment of patient history and concurrent medications is essential to minimize drug interactions and optimize therapeutic outcomes. Nukast AB Tablet SR should be used under medical supervision, with dosage adjustments based on clinical response.